Trial reportFrontiers in endocrinology2026
Predictive value of OGTT parameters and clinical markers in gestational diabetes mellitus: a prospective randomized controlled trial from a tertiary center in Türkiye.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) remains a major obstetric concern, yet the optimal screening strategy and the prognostic value of oral glucose tolerance test (OGTT) parameters remain debated. We aimed to compare the diagnostic yield and clinical outcomes of a two-step OGTT strategy (50 g glucose challenge followed by 100 g OGTT) versus a one-step 75 g OGTT approach, and to evaluate the predictive performance of individual OGTT time points for pregnancy complications and treatment requirement. Methods: In this prospective randomized controlled trial, 1,439 pregnant women undergoing routine screening at 24-28 weeks of gestation were randomized to either a two-step OGTT strategy (n=719) or a one-step 75 g OGTT strategy (n=720). GDM was classified as diet-controlled or insulin-requiring. Maternal risk factors, obstetric outcomes, and neonatal outcomes were recorded. Receiver operating characteristic (ROC) analyses assessed the predictive ability of OGTT parameters for polyhydramnios and insulin requirement. Results: Overall GDM prevalence was 12.3%, including 8.4% diet-controlled and 3.9% insulin-requiring cases. The one-step strategy identified a numerically higher proportion of GDM without significant differences in maternal or neonatal outcomes compared with the two-step approach. Rates of polyhydramnios, hypertensive disorders, macrosomia, cesarean delivery, preterm birth, neonatal intensive care admission, small for gestational age (7.4%), and intrauterine growth restriction (4.2%) were comparable between groups. ROC analyses demonstrated that 2-hour OGTT values showed the strongest predictive performance for polyhydramnios (AUC up to 0.816) and insulin requirement (AUC up to 0.808), whereas the 50 g screening test showed only moderate discrimination. Conclusion: The one-step 75 g OGTT increases diagnostic labeling without improving short-term clinical outcomes. Post-load OGTT values-particularly 2-hour glucose levels-provide the most clinically meaningful prognostic information and may support a risk-stratified approach to GDM management rather than expansion of diagnostic thresholds alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.